Patents Represented by Attorney Barbara L. Lences

Find this attorney in the Justia Lawyer Directory

  • Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7297705
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: August 19, 2004
    Date of Patent: November 20, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Derek Cecil Cole, William Joseph Lennox
  • Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7291736
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: November 6, 2007
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Ronald Charles Bernotas
  • Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7288561
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a CNS disorder related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: October 30, 2007
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Magda Asselin
  • Terphenyl guanidines as ?-secretase inhibitors
    Patent number: 7285682
    Abstract: The present invention provides terphenyl guanidine compounds of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: October 23, 2007
    Assignee: Wyeth
    Inventor: Baihua Hu
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7282495
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: October 16, 2007
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7271180
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: September 18, 2007
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7259165
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: August 21, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7238696
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: July 3, 2007
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7220756
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: May 22, 2007
    Assignee: Wyeth
    Inventor: Derek Cecil Cole
  • 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7074792
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: July 11, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler Adam Antane
  • Methods and compositions useful for the prediction of blood-brain barrier permeation
    Patent number: 7060428
    Abstract: The present invention provides a method for the in vitro determination of the ability of a compound or a mixture of compounds to permeate the blood-brain barrier and a membrane composition useful therefor.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: June 13, 2006
    Assignee: Wyeth
    Inventors: Li Di, Edward Harvel Kerns
  • 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7057039
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Hassan Mahmoud Elokdah, David Zenan Li
  • N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 7041695
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: May 9, 2006
    Assignee: Wyeth
    Inventor: Derek Cecil Cole
  • 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7034029
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: April 25, 2006
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7022701
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: April 4, 2006
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Joseph Raymond Stock, William Joseph Lennox, Ping Zhou
  • 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6995176
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: February 7, 2006
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek
  • (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6951881
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: October 4, 2005
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Michael Gerard Kelly, Byron Abel Bravo, Yvette Latko Palmer
  • 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6919354
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: July 19, 2005
    Assignee: Wyeth
    Inventors: Ping Zhou, Michael Gerard Kelly
  • Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 6906095
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a disorder relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 9, 2003
    Date of Patent: June 14, 2005
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Michael Gerard Kelly, David Scott Nunn, Lynne Padilla Greenblatt
  • Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
    Patent number: 6903112
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: June 7, 2005
    Assignee: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox